WMG Financial Advisors LLC Has $221,000 Position in Johnson & Johnson (NYSE:JNJ)

WMG Financial Advisors LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,527 shares of the company’s stock after selling 99 shares during the period. WMG Financial Advisors LLC’s holdings in Johnson & Johnson were worth $221,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Wealth Group Ltd. acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $213,000. Swedbank AB increased its stake in shares of Johnson & Johnson by 5.3% in the third quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after buying an additional 111,570 shares in the last quarter. ASB Consultores LLC raised its holdings in shares of Johnson & Johnson by 5.2% in the third quarter. ASB Consultores LLC now owns 5,061 shares of the company’s stock valued at $820,000 after buying an additional 248 shares during the last quarter. United Advisor Group LLC lifted its position in Johnson & Johnson by 18.7% during the 3rd quarter. United Advisor Group LLC now owns 5,563 shares of the company’s stock worth $902,000 after buying an additional 876 shares in the last quarter. Finally, Clarity Financial LLC grew its stake in shares of Johnson & Johnson by 9.7% during the third quarter. Clarity Financial LLC now owns 6,371 shares of the company’s stock valued at $1,032,000 after purchasing an additional 561 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the topic of several recent research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 19th. Bank of America raised their target price on Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a report on Wednesday. Leerink Partners cut their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Finally, Raymond James cut their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Insider Activity

In related news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Down 0.1 %

NYSE:JNJ opened at $165.22 on Thursday. The company has a market cap of $397.79 billion, a PE ratio of 24.85, a PEG ratio of 2.56 and a beta of 0.52. The stock has a 50-day simple moving average of $152.11 and a 200 day simple moving average of $156.19. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company earned $2.29 earnings per share. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. Johnson & Johnson’s dividend payout ratio is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.